Behavioral Health Business October 11, 2024
Biotech firm MARAbio has raised $19 million in a Series A funding round to accelerate the launch of its blood test for detecting maternal autoantibody-related (MAR) autism.
The Salt Lake City, Utah-based biotech company plans to use the funds to bring its proprietary blood testing technology to market. MAR autism is linked to specific patterns of autoantibodies in mothers and is present in an estimated 20% of those with an autism diagnosis.
The round was led by investment management firm MAK Capital One and is open to new investors through the end of 2024. The company is seeking an additional $9.9 million, according to publicly available documents.
MARAbio plans to make its blood test available to providers, including ABA providers,...
Today's Sponsors
Today's Sponsor